Drug Trial Radar · NCT00829192
Phase II AK Study in Organ Transplant Patients
Last checked: Nov 20, 2026Latest source record: Dec 6, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 2007
Primary completion
Jul 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Clinuvel Pharmaceuticals LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jan 26, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether afamelanotide (CUV1647) is effective in reducing the number of actinic keratoses and squamous cell carcinomas developing in immune compromised organ transplant recipients, who are at particularly high risk, over a 24 month test period. The number of lesions formed on the head, hands and forarms will be monitored over this 24 month test period.
Conditions
- Actinic Keratoses
- Carcinoma, Squamous Cell
- Organ Transplant Recipients
Interventions
Afamelanotide (CUV1647)Drug
16 mg subcutaneous implant administered every 60 days
PlaceboDrug
Placebo subcutaneous implant administered every 60 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the effect of afamelanotide (CUV1647) administered from slow release subcutaneous implants on the number of actinic keratoses (AKs) on the head, forearms and back of handsTime frame: 24 months
Locations
12 sites in 7 countries. Site status is shown where the registry gives one.
The Princess Alexandra Hospital
Brisbane, Queensland, Australia
The Queen Elizabeth Hospital
Adelaide, South Australia, Australia
The Royal Melbourne Hospital
Melbourne, Victoria, Australia
Hospital Erasme
Brussels, Belgium
Gent University Hospital
Ghent, Belgium
University Hospital
Besançon, France
Charité Univeritätsklinikum
Berlin, Germany
Kiel University Hospital
Kiel, Germany
Ospedali Riuniti di Bergamo
Bergamo, Italy
University of Padua
Padua, Italy
Karolinska University Hospital
Stockholm, Sweden
Universitätsspital Zürich
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.